Celcuity Inc. (NASDAQ:CELC) Short Interest Down 11.5% in November

Celcuity Inc. (NASDAQ:CELC) saw a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 3,090,000 shares, a decrease of 11.5% from the October 31st total of 3,490,000 shares. Based on an average daily volume of 266,900 shares, the short-interest ratio is currently 11.6 days.

Celcuity Trading Down 0.4 %

CELC stock traded down $0.05 during midday trading on Friday, reaching $12.80. The company’s stock had a trading volume of 140,762 shares, compared to its average volume of 305,348. Celcuity has a 52 week low of $11.51 and a 52 week high of $22.19. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The stock has a market cap of $475.26 million, a PE ratio of -4.90 and a beta of 0.76. The business’s 50-day simple moving average is $14.70 and its 200-day simple moving average is $15.72.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on CELC shares. Stifel Nicolaus lifted their price target on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a report on Monday, October 7th. Lifesci Capital began coverage on shares of Celcuity in a research report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Celcuity in a research report on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research note on Friday, November 15th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Celcuity currently has an average rating of “Buy” and an average target price of $29.17.

Hedge Funds Weigh In On Celcuity

Hedge funds have recently added to or reduced their stakes in the stock. Samlyn Capital LLC grew its holdings in shares of Celcuity by 92.4% in the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock valued at $21,735,000 after buying an additional 637,190 shares during the period. State Street Corp grew its position in shares of Celcuity by 152.2% in the 3rd quarter. State Street Corp now owns 1,107,415 shares of the company’s stock valued at $16,512,000 after purchasing an additional 668,318 shares during the period. Braidwell LP increased its stake in Celcuity by 71.2% during the 3rd quarter. Braidwell LP now owns 884,306 shares of the company’s stock worth $13,185,000 after purchasing an additional 367,663 shares in the last quarter. Vanguard Group Inc. raised its holdings in Celcuity by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock worth $17,898,000 after buying an additional 7,821 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Celcuity by 27.6% in the third quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock valued at $9,401,000 after buying an additional 136,518 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.